Who we are

The Anticancer Fund brings together highly qualified people from different areas of practice. Through cooperation and knowledge sharing, these people constantly strive to improve the information flow on cancer. The Anticancer Fund is currently in the process of hiring staff and building a network of experts in the field who will support our mission and critically review our assessment reports.

  • Luc Verelst, Chairman

    Luc Verelst founded Reliable Cancer Therapies in 2009 to provide information on reliable cancer treatments and to fund the development of a number of promising therapies. 4 years later, it evolved into the Belgian Anticancer Fund, a nonprofit private foundation. After graduating as a bioengineer from the Catholic University of Leuven (K.U. Leuven), Belgium in 1976, he founded several construction and real estate companies which grew into an international real estate group (Verelst, Eurinpro and Uplace). Over the years he sold most of the real estate business and moved to Switzerland, his new home. He has remained active as an investor in several high-tech and healthcare companies. In 2000 Luc also created Solid International, a non-profit organization that supports sustainable progress in developing countries by focusing on economic growth and education.

  • Lydie Meheus, Managing Director

    Lydie Meheus, PhD, is Managing Director of the Anticancer Fund (ACF) and Executive Director of Reliable Cancer Therapies (RCT). She holds a PhD in Protein Biochemistry. In 1987, Meheus began work as a senior researcher at Innogenetics, Belgium, where she subsequently held numerous positions. When Innogenetics incorporated its therapeutic activities into a new company, GENimmune, in 2007, she became Vice President for R&D. She began working at RCT in 2009 and at ACF in 2013.
     

  • Klara Rombauts, MSc

    Klara started working for Reliable Cancer Therapies in November 2009 as a scientist responsible for all activities related to natural products (medicinal plants and food supplements) and also responsible for the content of these topics on this website.  She is personally supervised in pharmacognosy by Professor Dr. Emeritus A.J. Vlietinck (Professor Emeritus of Pharmacognosy, University of Antwerp). Klara is a qualified Industrial Engineer, specializing in Biochemistry. She worked as a medicinal chemist Tibotec (J&J). At the Anticancer Fund Klara also coordinates the questions from patients and their families who contact our organization via the website.
     

  • Gauthier Bouche, MD

    Gauthier is the Medical Director of the Anticancer Fund. He holds a MD from the University of Poitiers, France and a MPH from the University of Bordeaux, France. After a few years as assistant professor in public health, epidemiology and clinical research at the University of Poitiers, his main focus is now on clinical research in cancer.
    He is responsible for the content of the "cancers" and "guides for patients-cancer types" sections of this website.
     

  • Ana Ugarte, MD

    Ana joined our team in October 2010, she is a project manager. Ana holds an MD degree and a Specialization in Tropical Medicine and Health Services Organization awarded by the Universidad Mayor de San Simon in Cochabamba, Bolivia. She also holds a Master degree in Public Health Methodology from the Free University of Brussels in Belgium and a Master degree in Advanced Oncology from the Ulm University in Germany. Before joining the Anticancer Fund Ana worked as an independent clinician and later as a researcher for the Institute of Human Development in Cochabamba, Bolivia.

  • Lieve Vanschoubroek, MSc

    Lieve started as a scientist in November 2010 at Reliable Cancer Therapies. She graduated in Pharmacy in 1985 at the University of Ghent and worked for several years as the editorial head of a scientific bilingual magazine for GPs. At the Anticancer Fund, Lieve is responsible for the investigation of specific diets, diet-related treatments and "lifestyle changes".

  • Kristine Beckers, MSc

    Kristine joined the Anticancer Fund (ACF) in 2014 as a scientist. She holds a Master’s Degree in Biomedical Sciences, obtained in 2007 at the Catholic University of Leuven. Before joining ACF, Kristine worked for Johnson & Johnson’s Clinical Trial Department in Beerse, Belgium for six years, first as CRA and later as Project Manager. She managed phase I to III clinical trials in oncology and haematology throughout the Benelux. Kristine is responsible for several ACF-supported clinical trials with repurposed drugs. Additionally, she works on patient support activities.

  • An Van Nuffel, Ph.D.

    An joined the Anticancer Fund in August 2014. An graduated as a Master in Biomedical Sciences from the University of Brussels (VUB, Belgium) in 2005. She worked on immune therapy at the Laboratory of Molecular and Cellular Therapy from the VUB. She was involved in the preclinical optimization of a dendritic cell therapy and performed immune monitoring of clinical trials with dendritic cells.  The latter resulted in a PhD degree in Medical sciences in 2012.  From 2012 to 2014 she worked at Reliable Cancer Therapies and Etherna, a spin-off from the University of Brussels. She is responsible for the content of the 'cell-based therapies' section of this website.

  • Fabienne Van de Keere, Ph.D.

    Fabienne joined the Anticancer Fund (ACF) in September 2014. She holds a PhD in Immunology and a Master’s in Biology from the Catholic University of Leuven (UCL). She also earned a Master on Technological Innovation Management from Saint-Louis University. Prior to ACF, Fabienne carried out basic research on HIV and autoimmune diseases at various institutions in Belgium and the US: de Duve Institute of Cellular Pathology (UCL), Yale University, Massachusetts Institute of Technology and at Shionogi Bioresearch. She then worked as an analyst at Mazerine Partners advising clients on investments in the Life Science sector. At ACF, Fabienne focuses on cellular immunotherapies.

  • Pan Pantziarka

    Pan Pantziarka, based in London, is a scientist working at Anticancer Fund (ACF). He is the joint co-ordinator of the Repurposing Drugs in Oncology project that the ACF has founded in partnership with the US not-for-profit organsiation Global Cures. In addition to looking at re-using existing non-cancer drugs as new sources of cancer treatments, the project also looks at the social and institutional factors influencing cancer policy. By training Pan is a data scientist and author but has switched fields to oncology. He has previously published in the area of cancer pre-disposition syndromes and is also chairman of the George Pantziarka TP53 Trust.

  • Sarah Vandenbroeck

    Team Assistant

  • Rica Capistrano, Ph.D.

    Rica graduated as Pharmacist in 2010 at the University of Antwerp. She obtained a PhD degree in Pharmaceutical Sciences in March 2015. Her PhD study on standardized plant extracts with potential anticancer effect was performed in collaboration with the Anticancer Fund. She joined the Anticancer Fund in July 2015, where she coordinates personalized information for patients and their families including off-label use and access to new drugs.

  • Ilse Rooman, Ph.D.

    Ilse Rooman obtained her PhD in 2002 at the Vrije Universiteit Brussel in Belgium. She completed postdoctoral studies at the Vrije Universiteit Brussel and at the Institut Hospital del Mar d'Investigacions Mèdiques in Spain. From 2011-2016 she was a laboratory head at the Garvan Institute of Medical Research, Australia. Currently she has a position as Professor at the Vrije Universiteit Brussel in the Laboratory of Medical and Molecular Oncology. She investigates the biology of the pancreas, and the development of pancreatic diseases such as pancreatitis and pancreatic cancer in experimental mouse models, directly informed by large -omics analysis of patient samples. At the Anticancer Fund, she manages all projects related to pancreatic cancer.